ArticleNature communications2022

Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors.

Elisa I Rivas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.